Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Non-small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT00569296
What this trial is testing

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Roger Williams Medical Center 5
Testing effectiveness (Phase 2)Study completedNCT04691388
What this trial is testing

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Who this might be right for
NSCLC
Zhejiang Cancer Hospital 29
Large-scale testing (Phase 3)Study completedNCT01168973
What this trial is testing

Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 1,253
Early research (Phase 1)Ended earlyNCT01746810
What this trial is testing

IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors

Who this might be right for
Recurrent Non-small Cell Lung Cancer
New Mexico Cancer Research Alliance 1
Testing effectiveness (Phase 2)Study completedNCT00777179
What this trial is testing

Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

Who this might be right for
NSCLC
Genzyme, a Sanofi Company 117
Early research (Phase 1)Ended earlyNCT06585488
What this trial is testing

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Who this might be right for
Metastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Colorectal Cancer+4 more
BeOne Medicines 47
Testing effectiveness (Phase 2)Study completedNCT00003103
What this trial is testing

Chemotherapy in Treating Patients With Solid Tumors

Who this might be right for
Bladder CancerBreast CancerColorectal Cancer+7 more
Memorial Sloan Kettering Cancer Center 57
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Large-scale testing (Phase 3)Study completedNCT00078260
What this trial is testing

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 589
Testing effectiveness (Phase 2)Looking for participantsNCT07602842
What this trial is testing

IDP-001 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorHead and Neck Squamous Cell Carcinoma+6 more
InduPro, Inc. 132
Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT03539536
What this trial is testing

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AbbVie 270
Testing effectiveness (Phase 2)Study completedNCT00251498
What this trial is testing

Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Veeda Oncology 82
Testing effectiveness (Phase 2)Study completedNCT00283244
What this trial is testing

Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

Who this might be right for
Lung Cancer
UNC Lineberger Comprehensive Cancer Center 147
Testing effectiveness (Phase 2)Ended earlyNCT03256721
What this trial is testing

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
Fuzhou General Hospital 37
Testing effectiveness (Phase 2)Ended earlyNCT02109016
What this trial is testing

Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Who this might be right for
Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLC+6 more
Clovis Oncology, Inc. 18
Large-scale testing (Phase 3)Looking for participantsNCT06627647
What this trial is testing

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
AstraZeneca 1,160
Large-scale testing (Phase 3)UnknownNCT00006048
What this trial is testing

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
AstraZeneca
Next Page